8-K: Harrow Secures Exclusive U.S. Rights for FDA-Approved Ophthalmic Steroid BYQLOVI from Formosa Pharmaceuticals

Harrow, Inc. has entered into an exclusive licensing agreement with Formosa Pharmaceuticals for the U.S. commercial rights to BYQLOVI, an FDA-approved ophthalmic steroid for post-operative inflammation and pain following ocular surgery.

Summary

• Harrow, Inc. and its wholly-owned subsidiary have entered into a license and supply agreement with Formosa Pharmaceuticals, Inc. for the exclusive U.S. commercial rights and marketing authorization of BYQLOVI (clobetasol propionate ophthalmic suspension) 0.05%.
• BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain following ocular surgery.
• Harrow will make a one-time payment of $500,000 to Formosa upon its first commercial sale of BYQLOVI to a third party.
• Formosa will also be eligible to receive other one-time payments based on the achievement of commercial gross profit milestones, along with royalties on gross profits of BYQLOVI.
• Harrow expects BYQLOVI to be available in the U.S. market in the fourth quarter of 2025.
• BYQLOVI is highlighted as the first new ophthalmic steroid in its class in over 15 years.
• The product is formulated using Formosa's proprietary APNT nanoparticle formulation technology, designed to provide a highly uniform suspension, minimize particle setting, and ensure consistent dosing.

Sentiment

Score: 8

Explanation: The announcement is highly positive for Harrow, securing exclusive rights to a newly FDA-approved, 'best-in-class' product with significant market potential and favorable clinical attributes. The financial terms involve an upfront payment only upon first commercial sale and ongoing royalties/milestones, which is a favorable structure. The risks mentioned are standard for pharmaceutical companies and forward-looking statements.

Positives

• Harrow has acquired exclusive U.S. commercial rights to an FDA-approved, clinically differentiated ophthalmic steroid, BYQLOVI.
• BYQLOVI is the first new ophthalmic steroid in its class in over 15 years, indicating significant market novelty and potential.
• The product demonstrated strong efficacy in pivotal clinical studies, with 77% and 85% of patients reporting no pain at Day 4 post-surgery, and 82% and 87% reporting no pain at Day 8.
• BYQLOVI showed significant inflammation clearance, with 33% and 30% of patients having zero cell counts in the anterior chamber at Day 8 post-surgery.
• It boasts a favorable safety profile with only 1.4% of patients experiencing elevated intraocular pressure (IOP), a substantially lower rate compared to other ophthalmic steroids.
• The dosing regimen is patient-friendly, requiring only 1 drop BID for 14 days, without the need for a loading dose or maintenance phase.
• The agreement positions Harrow to potentially shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment, which sees over 7 million annual surgeries.
• The payment structure is favorable for Harrow, with the initial $500,000 payment contingent upon the first commercial sale.

Negatives

• Harrow is obligated to make a one-time payment of $500,000 to Formosa upon the first commercial sale of BYQLOVI.
• Formosa will receive additional one-time payments based on commercial gross profit milestones and ongoing royalties on gross profits, which will impact Harrow's future profitability from BYQLOVI sales.
• Ocular adverse reactions occurring in ≥1% of subjects in clinical studies included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%), and vitreous detachment (1%), though many may be consequences of the surgical procedure.

Risks

• Risks related to Harrow's liquidity or results of operations.
• Uncertainty regarding Harrow's ability to successfully implement its business plan, develop and commercialize products, product candidates, and proprietary formulations in a timely manner or at all.
• Challenges in identifying and acquiring additional products.
• Difficulties in managing pharmacy operations and servicing debt.
• Risks associated with obtaining necessary financing to operate the business.
• Challenges in recruiting and retaining qualified personnel.
• Risks related to managing any growth Harrow may experience and successfully realizing the benefits of previous and future acquisitions and collaborative arrangements.
• Competition from pharmaceutical companies, outsourcing facilities, and pharmacies.
• General economic and business conditions, including inflation and supply chain challenges.
• Regulatory and legal risks, including litigation matters, and other uncertainties related to pharmacy operations and the pharmaceutical business.
• Uncertainty regarding physician interest in and market acceptance of Harrow's current and any future formulations and compounding pharmacies generally.
• Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision.
• Prolonged use of corticosteroids may result in posterior subcapsular cataract formation.
• The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
• In diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.
• Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections (bacterial, viral, fungal).

Future Outlook

Harrow expects BYQLOVI to be available in the U.S. market in the fourth quarter of 2025. The company anticipates that BYQLOVI has the potential to significantly impact the multi-billion-dollar U.S. post-surgical care ophthalmic segment by shifting the paradigm with its compelling efficacy, extraordinary safety, and patient-friendly dosing.

Management Comments

• Mark L. Baum, Chief Executive Officer of Harrow, stated: "We are thrilled to soon launch BYQLOVI, a truly clinically differentiated topical corticosteroid, into a U.S. market that now exceeds 7 million annual ophthalmic surgeries. With compelling efficacy, extraordinary safety, and patient-friendly dosing, BYQLOVI has the potential to shift the paradigm in the multi-billion-dollar U.S. post-surgical care ophthalmic segment."
• Erick Co, President and CEO of Formosa Pharmaceuticals, commented: "Harrow’s commitment to innovation, patient access, and physician engagement closely aligns with our mission to promote unique clinical advancements that improve patient outcomes. We are confident that Harrow’s leadership in the U.S. eyecare space will ensure BYQLOVI’s successful adoption among surgeons and eyecare professionals – and ultimately, better post-surgical experiences for U.S. patients."

Industry Context

The U.S. ophthalmic surgery market is substantial, exceeding 7 million annual procedures, making the post-surgical care segment a multi-billion-dollar opportunity. BYQLOVI's approval as the first new ophthalmic steroid in its class in over 15 years positions it as a significant new entrant. This aligns with a broader industry trend towards specialized, high-efficacy treatments for specific medical needs, potentially disrupting existing treatments and offering a 'best-in-class' option for post-operative inflammation and pain.

Comparison to Industry Standards

• **Pain Relief**: BYQLOVI demonstrated 77% and 85% of patients reporting no pain at Day 4 post-surgery, and 82% and 87% reporting no pain at Day 8 post-surgery, positioning it as "Best-in-Class Pain Relief" compared to unspecified industry standards for post-operative ocular pain.
• **Inflammation Clearance**: Achieved 33% and 30% of patients with zero cell counts in the anterior chamber at Day 8 post-surgery, touted as "Best-in-Class Inflammation Clearance" relative to other treatments for post-operative ocular inflammation.
• **Safety (IOP Elevation)**: Only 1.4% of patients experienced elevated intraocular pressure (IOP), which is stated to be a "substantially lower rate compared to other ophthalmic steroids," indicating a superior safety profile regarding this common corticosteroid side effect.
• **Dosing Regimen**: Offers "Best-in-Class Post-Surgical Dosing" at 1 drop BID for 14 days, eliminating the need for a loading dose and maintenance phase, which is a significant improvement in patient convenience and adherence compared to multi-dose or tapering regimens common with other ophthalmic steroids.

Stakeholder Impact

• **Shareholders**: Potential for increased revenue, market share, and long-term growth for Harrow due to the addition of a differentiated, FDA-approved product. Formosa shareholders benefit from licensing revenue, milestone payments, and royalties.
• **Patients**: Access to a new, potentially "best-in-class" treatment for post-operative inflammation and pain following ocular surgery, offering improved safety and dosing convenience.
• **Eyecare Professionals/Surgeons**: A new, effective treatment option for post-ocular surgery care, potentially leading to better patient outcomes and simpler treatment regimens.
• **Competitors**: Increased competition in the ophthalmic steroid market, particularly for post-surgical care, which may necessitate strategic responses from existing players.

Next Steps

• Harrow to make a one-time payment of $500,000 to Formosa upon its first commercial sale of BYQLOVI to a third party.
• Harrow to launch BYQLOVI in the U.S. market.
• Harrow expects BYQLOVI to be available in the fourth quarter of 2025.
• Formosa to receive additional one-time payments based on commercial gross profit milestones.
• Formosa to receive royalties on gross profits of BYQLOVI.

Key Dates

Recommendation

Keywords

Harrow, Formosa Pharmaceuticals, BYQLOVI, clobetasol propionate ophthalmic suspension, ophthalmic steroid, ocular surgery, post-operative inflammation, pain relief, FDA approval, licensing agreement, eyecare pharmaceutical, APNT nanoparticle technology, intraocular pressure, glaucoma, cataracts, corneal edema, anterior chamber inflammation, cystoid macular edema, pharmaceuticals, biotechnology